Preview

Медицинский Совет

Расширенный поиск

Lactobacillus rhamnosus GG: клинические аспекты применения с позиций доказательной медицины


https://doi.org/10.21518/2079-701X-2018-17-66-73

Полный текст:

Аннотация

В настоящем обзоре представлена информация о составе и функциях микробиоты кишечника, ее роли в формировании иммунитета. В настоящее время достаточно широко распространено профилактическое и терапевтическое применение пробиотиков при самых разных патологических состояниях, однако доказанной эффективностью они обладают лишь при некоторых заболеваниях. В данном обзоре приведены сведения об эффективности использования в педиатрической практике пробиотического микроорганизма L. rhamnosus GG как одного из наиболее изученных и апробированных штаммов. Суммированы имеющиеся на сегодняшний день доказательные данные относительно эффективности его использования для лечения острой диареи, профилактики антибиотик-ассоциированной диареи и нозокомиальных инфекций, определено место L. rhamnosus GG в профилактике инфекций дыхательных путей и ЖКТ у детей, рассмотрено лечебное и профилактическое использование при аллергических заболеваниях и других нозологических формах. Особо отмечено влияние L. rhamnosus GG на функционирование иммунной системы. Обнадеживающими являются результаты испытаний этого штамма как адъюванта вакцин. В обзоре описаны молекулярные механизмы действия L. rhamnosus GG, обеспечивающие иммуномодулирующее действие данного штамма. Кроме того, представлены данные о клинической эффективности разрешенного к применению в России синбиотика Нормобакт L, включающего комбинацию LGG (4 х 109) и фруктоолигосахаридов (800 мг) у детей.

Об авторах

А. В. Горелов
ФБУН «Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

Горелов Александр Васильевич – профессор, член-корреспондент РАН, заведующий клиническим отделом инфекционной патологии ФБУН «Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора», профессор кафедры детских болезней ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

Москва



Е. В. Каннер
ФБУН «Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора»
Россия

Каннер Екатерина Валерьевна – кандидат медицинских наук, старший научный сотрудник

Москва



M. Л. Максимов
Казанская государственная медицинская академия – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия

Максимов Максим Леонидович – доктор медицинских наук, профессор кафедры клинической фармакологии и фармакотерапии



А. С. Ермолаева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

Ермолаева Анна Саввична – кандидат медицинских наук, доцент кафедры клинической фармакологии и пропедевтики внутренних болезней

Москва

 



А. А. Вознесенская
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

Вознесенская Анастасия Александровна

Москва



К. Н. Дадашева
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»
Россия

Дадашева Карина Николаевна – врач-дерматолог

Москва



Список литературы

1. Андреева И.В. Потенциальные возможности применения пробиотиков в клинической практике. Клиническая микробиология, антимикробная химиотерапия, 2006, 8(2): 151–172.

2. Gorbach SL, Goldin BR. Lactobacillus strains and methods of selection. US Patent. N 4839281.

3. Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci, 1987, 70(1): 1–12.

4. Ouwehand AC, Saxelin M, Salminen S. Phenotypic differences between commercial Lactobacillus rhamnosus GG and L. rhamnosus strains recovered from blood. Clin Infect Dis, 2004, 39: 1858–1860.

5. Sullivan A, Nord CE. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis, 2006, 38: 327–331.

6. Salminen MK, Tynkkynen S, Rautelin H, Poussa T, Saxelin M, Ristola M, Valtonen V, Jarvinen A. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials, 2004, 5: 183–191. doi: 10.1310/6F83-N39Q-9PPP-LMVV.

7. Luoto R, Isolauri E, Lehtonen L. Safety of Lactobacillus GG probiotic in infants with very low birth weight: twelve years of experience. Clin Infect Dis, 2010, 50: 1327–1328.

8. Manzoni P, Lista G, Gallo E, Marangione P, Priolo C, Fontana P, Guardione R, Farina D. Routine Lactobacillus rhamnosus GG administration in VLBW infants: a retrospective, 6-year cohort study. Early Human Development,2011, 87(Suppl 1): 35–38.

9. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet, 2001, 357: 1076–1079. doi: 10.1016/S01406736(00)04259-8.

10. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics, 2008, 121: e850– 856. doi: 10.1542/peds.2007-1492.

11. Boyle RJ, Mah LJ, Chen A, Kivivuori S, RobinsBrowne RM, Tang ML. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin Exp Allergy, 2008, 38: 1882–1890.

12. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med, 2010, 182: 1058–1064.

13. Lebeer S, Vanderleyden J, de Keersmaecker SC. Molecular study of adaptation and probiotic factors in Lactobacillus rhamnosus GG. KU Leuven, Faculty of Bioengineering sciences, 2008.

14. Kankainen M, Paulin L, Tynkkynen S, von Ossowski I, Reunanen J, Partanen P, Satokari R, Vesterlund S, Hendrickx APA, Lebeer S. et al. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a humanmucus binding protein. Proceedings of the National Academy of Sciences, 2009, 106: 17193–17198.

15. Douillard FP, Ribbera A, Kant R, Pietila TE, Jarvinen HM, Messing M, Randazzo CL, Paulin L, Laine P, Ritari J. et al. Comparative Genomic and Functional Analysis of 100 Lactobacillus rhamnosus Strains and Their Comparison with Strain GG. PLoS Genet, 2013, 9: e1003683.

16. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci, 1992, 37: 121–128.

17. Sepp E, Mikelsaar M, Salminen S. Effect of Administration of Lactobacillus-Casei Strain Gg on the Gastrointestinal Microbiota of Newborns. Microbial Ecology in Health and Disease,1993, 6: 309–314.

18. Van den Abbeele P, Roos S, Eeckhaut V, MacKenzie DA, Derde M, Verstraete W, Marzorati M, Possemiers S, Vanhoecke B, Van Immerseel F, Van de Wiele T. Incorporating a mucosal environment in a dynamic gut model results in a more representative colonization by lactobacilli. Microb Biotechnol, 2012, 5: 106–115.

19. Alander M, Korpela R, Saxelin M, VilpponenSalmela T, Mattila-Sandholm T, von Wright A. Recovery of Lactobacillus rhamnosus GG from human colonic biopsies. Lett Appl Microbiol, 1997, 24: 361–364.

20. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, MattilaSandholm T, von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol, 1999, 65: 351–354.

21. Kumpu M, Swanljung E, Tynkkynen S, Hatakka K, Kekkonen RA, Jarvenpaa S, Korpela R, Pitkaranta A. Recovery of probiotic Lactobacillus rhamnosus GG in tonsil tissue after oral administration: randomised, placebocontrolled, doubleblind clinical trial. British Journal of Nutrition, 2013, 109: 2240–2246.

22. Colodner R, Edelstein H, Chazan B, Raz R. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr Med Assoc J, 2003, 5: 767–769.

23. Yli-Knuuttila H, Snall J, Kari K, Meurman JH. Colonization of Lactobacillus rhamnosus GG in the oral cavity. Oral Microbiol Immunol, 2006, 21: 129–131.

24. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol, 2001, 8: 293-296.

25. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol, 1999, 276: G941-50.

26. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKCand MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol, 2008, 294: G1060-9.

27. Tao Y, Drabik KA, Waypa TS, Musch MW, Alverdy JC, Schneewind O et al. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol, 2006, 290: C1018-30.

28. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem, 2002, 277: 50959– 50965. doi: 10.1074/jbc.M207050200.

29. Claes IJ, Schoofs G, Regulski K et al. Genetic and Biochemical Characterization of the Cell Wall Hydrolase Activity of the Major Secreted Protein of Lactobacillus rhamnosus GG. PLoS One, 2012, 7: e31588.

30. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble Proteins Produced by Probiotic Bacteria Regulate Intestinal Epithelial Cell Survival and Growth. Gastroenterology, 2007, 132: 562–575.

31. Banasaz M, Norin E, Holma R, Midtvedt T. Increased Enterocyte Production in Gnotobiotic Rats Mono-Associated with Lactobacillusrhamnosus GG. Appl Environ Microbiol, 2002, 68: 3031–3034.

32. Ruseler-van Embden JG, van Lieshout LM, Gosselink MJ, Marteau P. Inability of Lactobacillus casei strain GG, L. acidophilus, and Bifidobacterium bifidum to degrade intestinal mucus glycoproteins. Scand J Gastroenterol, 1995, 30: 675–680.

33. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis, 2002, 2: 171–179. doi: 10.1016/S14733099(02)00226-8.

34. Frosali S, Pagliari D, Gambassi G et al. How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology. Journal of Immunology Research, 2015, 2015: 489821. doi: 10.1155/2015/489821.

35. Miettinen M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M, et al. Lactobacilli and streptococci induce interleukin12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun, 1998, 66: 6058–6062.

36. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun, 1996, 64: 5403–5405.

37. Oksaharju A, Kankainen M, Kekkonen RA еt al. Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells. World J Gastroenterol, 2011, 17: 750– 759.

38. Miettinen M, Lehtonen A, Julkunen I, Matikainen S. Lactobacilli and Streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. J Immunol, 2000, 164: 3733–3740.

39. Miettinen M, Veckman V, Latvala S, Sareneva T, Matikainen S, Julkunen I. Live Lactobacillus rhamnosus and Streptococcus pyogenes differentially regulate Toll-like receptor (TLR) gene expression in human primary macrophages. J Leukoc Biol, 2008, 84: 1092–100.

40. Mu C, Yang Y, Zhu W. Crosstalk Between The Immune Receptors and Gut Microbiota. Curr Protein Pept Sci, 2015, 16(7): 622–631.

41. Maranduba CM da C, De Castro SBR, de Souza GT et al. Intestinal Microbiota as Modulators of the Immune System and Neuroimmune System: Impact on the Host Health and Homeostasis. Journal of Immunology Research, 2015, 2015: 931574. doi: 10.1155/2015/931574.

42. Belkaid Y, Harrison OJ. Homeostatic immunity and the microbiota. Immunity, 2017, 46(4): 562– 576. doi: 10.1016/j.immuni.2017.04.008.

43. Marianelli C, Cifani N, Pasquali P. Evaluation of antimicrobial activity of probiotic bacteria against Salmonella enterica subsp. enterica serovar typhimurium 1344 in a common medium under different environmental conditions. Res Microbiol, 2010, 161: 673–680.

44. De Keersmaecker SC, Verhoeven TL, Desair J, Marchal K, Vanderleyden J, Nagy I. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett, 2006, 259: 89–96.

45. Silva M, Jacobus NV, Deneke C, Gorbach SL. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother, 1987, 31: 1231–1233.

46. Makras L, Triantafyllou V, Fayol-Messaoudi D, Adriany T, Zoumpopoulou G, Tsakalidou E, Servin A, De Vuyst L. Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res Microbiol, 2006, 157: 241–247.

47. Hutt P, Shchepetova J, Loivukene K, Kullisaar T, Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against enteroand uropathogens. J Appl Microbiol, 2006, 100: 1324–1332.

48. Zhang Y, Zhang L, Du M, Yi H, Guo C, Tuo Y, Han X, Li J, Yang L. Antimicrobial activity against Shigella sonnei and probiotic properties of wild lactobacilli from fermented food. Microbiol Res, 2011, 167: 27–31.

49. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther, 2007, 25: 871–881. doi: 10.1111/j.1365-2036.2007.03282.x.

50. Szajewska H, Wanke M, Patro B. Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcareassociated diarrhoea in children. Aliment Pharmacol Ther, 2011, 34: 1079–1087. doi: 10.1111/j.1365-2036.2011.04837.x.

51. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children – updated analysis of randomised controlled trials. Aliment Pharmacol Ther, 2013, 38: 467–476. doi: 10.1111/apt.12403.

52. FAO/WHO. Working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for the evaluation of probiotics in food. 2002. ftp: //ftp.fao.org/es/esn/food/wgreport2.pdf

53. Supplementation of infant formula with probiotics and/or prebiotics: a systemic rewiew and comment by the ESPGHAN Commitee on Nutrition. J Pediatr Gastroenterol, 2011, 52(2): 238–250.

54. Oberhelman RA, Gilman RH, Sheen P, Taylor DN, Black RE, Cabrera L, Lescano AG, Meza R, Madico G. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr, 1999, 134: 15–20.

55. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 2011 Nov 9, 11: CD004827.

56. Applegate JA, Fischer Walker CL, Ambikapathi R, Black RE. Systematic review of probiotics for the treatment of community-acquired acute diarrhea in children. BMC Public Healt, 2013, 13(Suppl 3): S16.

57. Horvath A, Dziechciarz P, Szajewska H. Metaanalysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther, 2011, 33: 1302–1310.

58. Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systemic review. Gut, 2008, 64: 654–667.

59. Manzoni P, Mostert M, Leonessa ML, Priolo C, Farina D, Monetti C, Latino MA, Gomirato G. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis, 2006, 42: 1735–1742.

60. Gorbach SL, Chang TW, Goldin B. Successful Treatment of Relapsing Clostridium Difficile Colitis with Lactobacillus Gg. Lancet, 1987, 2: 1519–1519.

61. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of Recurrent Clostridium-Difficile Colitis with Lactobacillus Gg. J Pediatr Gastroenterol Nutr, 1995, 21: 224–226.

62. Aminabadi NA, Erfanparast L, Ebrahimi A, Oskouei SG. Effect of chlorhexidine pretreatment on the stability of salivary lactobacilli probiotic in sixto twelve-year-old children: a randomized controlled trial. Caries Res, 2011, 45: 148–154.

63. Nase L, Hatakka K, Savilahti E, Saxelin M, Ponka A, Poussa T, Korpela R, Meurman JH. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res, 2001, 35: 412–420.

64. Toiviainen A, Jalasvuori H, Lahti E, Gursoy U, Salminen S, Fontana M, Flannagan S, Eckert G, Kokaras A, Paster B, Soderling E. Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. Clin Oral Investig, 2014.

65. Hojsak I, Abdovic S, Szajewska H, Milosevic M, Krznaric Z, Kolacek S. Lactobacillus GG in the Prevention of Nosocomial Gastrointestinal and Respiratory Tract Infections. Pediatrics, 2010, 125: E1171–E1177.

66. Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, Maiuri L, Guarino A. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: A pilot study. Clinical Nutrition, 2007, 26: 322–328.

67. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebocontrolled trial. J Allergy Clin Immunol, 2007, 119: 1019–1021.

68. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet, 2003, 361: 1869–1871.

69. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet, 2001, 357: 1076–1079.

70. Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, Savilahti E. Lactobacillus GG effect in increasing IFNgamma production in infants with cow’s milk allergy. J Allergy Clin Immunol, 2004, 114: 131– 136.

71. Berni Canani R, Nocerino R, Terrin G, Frediani T, Lucarelli S, Cosenza L, Passariello A, Leone L, Granata V, Di Costanzo M. et al. Formula selection for management of children with cow’s milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study. J Pediatr, 2013, 163: 771–777 e771.

72. Pelto L, Isolauri E, Lilius EM, Nuutila J, Salminen S. Probiotic bacteria downregulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin Exp Allergy, 1998, 28: 1474–1479.

73. Doege K, Grajecki D, Zyriax BC, Detinkina E, Zu Eulenburg C, Buhling KJ. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood – a meta-analysis. Br J Nutr, 2011, 26: 1–6.

74. Gordon BR. The allergic march: Can we prevent allergies and asthma? Otolaryngol Clin North Am, 2011, 44: 765–777.

75. Lahtinen SJ, Boyle RJ, Kivivuori S, Oppedisano F, Smith KR, Robins-Browne R, Salminen SJ, Tang ML. Prenatal probiotic administration can influence Bifidobacterium microbiota development in infants at high risk of allergy. J Allergy Clin Immunol, 2009, 123: 499–501.

76. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol, 2002, 109: 119–121.

77. Boyle RJ, Ismail IH, Kivivuori S, Licciardi PV, Robins-Browne RM, Mah LJ, Axelrad C, Moore S, Donath S, Carlin JB, Lahtinen SJ, Tang ML. for the prevention of eczema: a randomized controlled trial. Allergy, 2011, 66: 509–516.

78. Bottcher MF, Abrahamsson TR, Fredriksson M, Jakobsson T, Bjorksten B. Low breast milk TGFbeta2 is induced by Lactobacillus reuteri supplementation and associates with reduced risk of sensitization during infancy. Pediatr Allergy Immunol, 2008, 19: 497–504.

79. Prescott SL, Wickens K, Westcott L, Jung W, Currie H, Black PN, Stanley TV, Mitchell EA, Fitzharris P, Siebers R, Wu L, Crane J. Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferongamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clin Exp Allergy, 2008, 38: 1606–1614.

80. Kuitunen M., Kukkonen A.K., Savilahti E. Impact of maternal allergy and use of probiotics during pregnancy on breast milk cytokines and food antibodies and development of allergy in children until 5 years. Int Arch Allergy Immunol, 2012, 159: 162–170.

81. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D . RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine, 1995, 13: 310–312.

82. de Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T, Schrezenmeir J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. European Journal of Nutrition, 2005, 44: 406–413.


Просмотров: 107


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)